Advertisement

Welcome to the new AJNR, Updated Hall of Fame, and more. Read the full announcements.

AJNR is seeking candidates for the position of Associate Section Editor, AJNR Case Collection. Read the full announcement.

 

Research ArticleBRAIN

Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis

Marco Rovaris, Giancarlo Comi, David Ladkani, Jerry S. Wolinsky and Massimo Filippi European/Canadian Glatiramer Acetate Study Group
American Journal of Neuroradiology January 2003, 24 (1) 75-81;

Article Figures & Data

Tables

  • TABLE 1:

    Baseline clinical and MR imaging characteristics of the study subjects

    CharacteristicPlacebo Group (n = 120)GA Group (n = 119)
    Age (y)34.0 ± 7.534.1 ± 7.4
    Disease duration (y)8.3 ± 5.57.9 ± 5.5
    Prior 2-year relapse rate2.5 ± 1.42.8 ± 1.8
    EDSS score2.4 ± 1.22.3 ± 1.1
    No. of Gd-enhancing lesions4.4 ± 7.14.2 ± 4.8
    Volume of lesions (cm3)
     Gd enhancing0.7 ± 2.20.6 ± 0.7
     Hyperintense on T2-weighted images20.5 ± 18.820.0 ± 17.2
     Hypointense on T1-weighted images4.0 ± 4.93.4 ± 3.9

    • Note.—Data are the mean ± SD.

  • TABLE 2:

    Univariate correlations between clinical and MR imaging measures of MS disease activity

    Variable 1*Variable 2*All Patients (n = 239)Placebo Group (n = 120)GA Group (n = 119)
    Pre-study relapsesOn-trial relapses0.21 (.001)0.19 (.04)0.25 (.006)
    Pre-study relapsesBaseline EL0.100.090.11
    Pre-study relapsesOn-trial EL0.15 (.02)0.140.20 (.03)
    Pre-study relapsesOn-trial new T2 lesions0.19 (.003)0.150.27 (.003)
    On-trial relapsesBaseline EL0.25 (<.001)0.30 (.001)0.22 (.02)
    On-trial relapsesOn-trial EL0.30 (<.001)0.36 (<.001)0.21 (.02)
    On-trial relapsesOn-trial new T2 lesions0.32 (<.001)0.34 (<.001)0.25 (.006)
    Baseline ELOn-trial EL0.64 (<.001)0.66 (<.001)0.65 (<.001)
    On-trial ELOn-trial new T2 lesions0.88 (<.001)0.90 (<.001)0.84 (<.001)

    • Note.—Values are the Spearman rank correlation coefficients. Data in parentheses are P values ≤.05.

    • * Pre-study relapses indicate the number of relapses during the 2 years prior to the study period; baseline EL, the number of Gd-enhancing lesions on the images obtained at study entry; and on-trial EL, the total number of Gd-enhancing lesions during the 9 months of the study.

  • TABLE 3:

    Univariate correlations between MR imaging measures of MS burden of disease and clinical disability

    MeasureEDSS Score, All Patients (n = 239)EDSS Score, Placebo Group (n = 120)EDSS Score, GA Group (n = 119)
    BaselineChangeBaselineChangeBaselineChange
    Baseline T2 LV0.28 (<.001)0.16 (.02)0.27 (.003)0.090.29 (.001)0.24 (.008)
    Baseline T1 LV0.19 (.003)0.18 (.006)0.24 (.009)0.120.120.23 (.01)
    T2 DLV0.130.17 (.007)0.120.100.100.25 (.005)
    T1 DLV0.17 (.007)0.18 (.006)0.160.090.20 (.03)0.31 (<.001)

    • Note.—Values are the Spearman rank correlation coefficients. Data in parentheses are P values ≤.05. DLV indicates the difference in lesion volume between month 9 images and baseline images; EDSS change, the difference in the EDSS score between month 9 evaluations and baseline evaluations; and LV, lesion volume.

  • TABLE 4:

    Univariate correlations between MR imaging measures of MS activity and burden of disease

    Variable 1*Variable 2*All Patients (n = 239)Placebo Group (n = 120)GA Group (n = 119)
    Baseline T2 LVOn-trial EL0.51 (<.001)0.55 (<.001)0.47 (<.001)
    Baseline T2 LVOn-trial new T2 lesions0.32 (<.001)0.40 (<.001)0.24 (.009)
    Baseline T2 LVT2 DLV0.37 (<.001)0.44 (<.001)0.30 (.001)
    Baseline T2 LVT1 DLV0.50 (<.001)0.48 (<.001)0.53 (<.0001)
    Baseline T1 LVOn-trial EL0.36 (<.001)0.41 (<.001)0.29 (.001)
    Baseline T1 LVOn-trial new T2 lesions0.19 (.003)0.28 (.002)0.10
    Baseline T1 LVT1 DLV0.29 (<.001)0.33 (<.001)0.24 (.009)
    Baseline T1 LVT2 DLV0.17 (.007)0.22 (0.02)0.13

    • Note.—Values are the Spearman rank correlation coefficients. Data in parentheses are P values ≤.05.

    • * DLV indicates the difference in lesion volume between month 9 images and baseline images; LV, lesion volume; on-trial EL, the total number of Gd-enhancing lesions during the 9 months of the study.

Back to top

In this issue

Advertisement
Print
Download PDF
Email Article
Cite this article
0 Responses
Respond to this article
Bookmark this article
Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis
Marco Rovaris, Giancarlo Comi, David Ladkani, Jerry S. Wolinsky, Massimo Filippi
American Journal of Neuroradiology Jan 2003, 24 (1) 75-81;
del.icio.us logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement